In the Sweet Spot · · Boston Scientific (BSX) · Healthcare
Why Boston Scientific stands out today
Boston Scientific sits 54% below its 52-week high with a PAR near the top of the sweet spot, pairing an elite quality profile with a projected return that reflects the market's repricing of the shares.
Boston Scientific (BSX) was Manifest Investing's In the Sweet Spot daily stock pick for August 11, 2026. At the time of the pick, Boston Scientific carried a quality percentile of 99 and a projected annual return (PAR) of 18.5% against a MIPAR of 8.9%, placing it inside the sweet spot of 13.9% to 18.9%.
Key metrics at the time of the pick
- Quality percentile
- 99
- Projected annual return (PAR)
- 18.5%
- MIPAR (median PAR of coverage)
- 8.9%
- PROVE
- 13.5%
- Core score (of 300)
- 291
- Financial strength (of 100)
- 97
- EPS stability (of 100)
- 94.4
- Sales growth forecast
- 10.9%
- P/E ratio
- 20.6
- Price at pick
- $50.46
- 52-week low
- $42.20
- 52-week high
- $109.50
- Above 52-week low
- 19.6%
- Below 52-week high
- 53.9%
- Dividend yield
- 0.0%
- Projected yield
- 0.0%
- In the sweet spot
- Yes
- Triple play
- No
Boston Scientific (BSX)
| **Quality 99.4 | PAR 18.5% | Core Score 291/300 | Price $50.46** |
With MIPAR (the median projected annual return across all stocks Manifest tracks) at 8.9%, the sweet spot band runs from 13.9% to 18.9%. Boston Scientific’s projected annual return of 18.5% sits near the top of that range, paired with a quality percentile of 99.4 — among the highest in our coverage. Financial strength ranks 97.3 out of 100 and EPS stability sits at 94.4, both elite readings, while the growth forecast behind the projection is a comparatively modest 10.9% annually. The sum of quality, financial strength, and EPS stability (core score) is 291, well above the 225 threshold many long-term investors use as a “core holding” screen.
Why the return projection is elevated right now
PAR moves inversely to price: when a high-quality company’s price falls sharply while its underlying fundamentals hold up, the projected return rises. BSX’s current price of $50.46 is 53.9% below its 52-week high of $109.50 (52-week range: $42.20–$109.50). That combination — a steep pullback alongside still-strong quality and financial-strength scores — is the textbook setup this feature exists to surface: not a claim that the stock is “cheap” in some absolute sense, but a data point worth studying because the market has repriced the shares meaningfully lower.
Bottom line for research purposes
Boston Scientific pairs an elite quality and core score profile with a PAR near the top of the sweet spot, a dynamic directly tied to a 54% pullback from its 52-week high. Understanding why the market has repriced the shares this much is exactly the kind of question worth digging into further — the fundamentals and valuation reset make this a company worth a closer look, not a buy or sell signal in themselves.
This is an educational highlight, not a recommendation. As always, weigh any decision against your own goals, risk tolerance, and further research.
About In the Sweet Spot
Manifest Investing's daily stock pick: one high-quality company whose projected annual return (PAR) sits in the sweet spot above the market median (MIPAR). Each pick pairs Manifest Investing's quality percentile with its projected annual return (PAR); the sweet spot runs from MIPAR + 5 to MIPAR + 10 percentage points. Browse every pick in the archive.
In the Sweet Spot is educational and is not investment advice or a recommendation to buy or sell any security. Figures reflect Manifest Investing's methodology as of the pick date.